Fibromyalgia: what the research says is happening in the body
What studies of the brain, nerves, and immune system have found in people with fibromyalgia, how the condition is diagnosed, and which treatments have held up in trials.

Fibromyalgia causes pain across the body along with fatigue, unrefreshing sleep, and trouble with memory and concentration. An analysis of a U.S. national health survey estimated that 1.75 percent of adults, about 3.94 million people, meet criteria for it. Of those, 73 percent said their doctor had given them a different diagnosis (Walitt et al., 2015).
For decades the condition was hard to study because standard blood tests, X-rays, and scans come back normal. That has changed. Brain imaging, skin biopsies, and antibody experiments have each found measurable differences in people with fibromyalgia. None of these is a diagnostic test yet, and researchers do not agree on a single cause.
This article is for adults who have fibromyalgia, or think they might, and want to know what the research has found and which treatments are supported by trials.
Who it affects
In the national survey, people who met the criteria reported high levels of pain and other symptoms, psychological distress, medical costs, and work disability (Walitt et al., 2015). In a survey of 800 patients in eight countries, 84 percent were women, most were between 36 and 59 years old, and they had been living with symptoms for an average of 6.5 years. Twenty-two percent said they were unable to work, and another 25 percent said they could not work all the time because of the condition (Choy et al., 2010).
How fibromyalgia is diagnosed
There is no lab test. Diagnosis rests on the pattern of symptoms. Under the 2016 revision of the American College of Rheumatology criteria, an adult qualifies when pain is present in at least four of five body regions, symptoms have lasted at least three months, and scores on two short questionnaires pass set thresholds. One questionnaire counts painful areas. The other rates fatigue, unrefreshing sleep, and cognitive symptoms. The revision also removed an older rule about excluding other diseases, so fibromyalgia can be diagnosed alongside other conditions (Wolfe et al., 2016).
Until 2010, diagnosis depended on a doctor pressing on 18 specific points on the body and finding at least 11 of them tender. That examination was replaced by questionnaires, partly because it was applied inconsistently and partly because it took no account of fatigue, sleep, and thinking problems.
Getting to a diagnosis often takes time. In the eight-country survey, people waited almost a year before seeing a doctor about their symptoms, and then took an average of 2.3 years and visits to 3.7 different physicians to be diagnosed (Choy et al., 2010).
What brain imaging shows
The best-supported explanation is that the central nervous system amplifies pain signals. In an early functional MRI study, researchers pressed on the thumbnail of people with fibromyalgia and of healthy volunteers. A low pressure that the patients felt as painful activated many pain-processing regions in their brains. The same pressure in healthy volunteers activated only two regions. The healthy volunteers needed a much higher pressure to reach the same level of pain, and at that point their brain activity looked similar to the patients' (Gracely et al., 2002).
A review in JAMA describes fibromyalgia as a state of central nervous system pain amplification that comes with fatigue, memory problems, and sleep and mood disturbance (Clauw, 2014). This is the reasoning behind using medications that act on the brain and spinal cord.
What skin biopsies show
Some people with fibromyalgia also have changes outside the brain. A meta-analysis of eight studies with 222 participants found that 49 percent had small fiber pathology, meaning loss of or damage to the thin nerve endings that carry pain and temperature signals. In the studies that used skin biopsy, the figure was 45 percent (Grayston et al., 2019).
Results varied between studies, and what the finding means is still debated. It may point to a subgroup of patients with a different underlying problem. It is also possible that the nerve changes are a result of the condition and not a cause.
The antibody experiment
In 2021 researchers reported that when they injected mice with antibodies purified from the blood of people with fibromyalgia, the mice became more sensitive to pressure and cold, moved less, lost grip strength, and lost nerve fibers in their skin. Antibodies from healthy people had no such effect, and neither did patient serum with the antibodies removed (Goebel et al., 2021).
The result suggests the immune system plays a part in at least some patients. It was an animal study. Whether treatments that lower these antibodies help people is still being tested, so the finding does not change care today.
Family history
Fibromyalgia runs in families. One study compared relatives of people with fibromyalgia to relatives of people with rheumatoid arthritis. The odds of having fibromyalgia were 8.5 times higher among the relatives of fibromyalgia patients (Arnold et al., 2004).
What trials show about treatment
Exercise has the most consistent support. European recommendations based on 107 systematic reviews gave a strong recommendation to only one therapy, exercise, and advise starting with education and non-drug approaches before medication (Macfarlane et al., 2017). A Cochrane review of 13 randomized trials with 839 people found that aerobic exercise improved quality of life by about 8 points and pain by about 11 points on 100-point scales, compared with no exercise. The evidence was rated low to moderate quality (Bidonde et al., 2017).
The same recommendations set out a sequence. Care starts with an explanation of the condition and with exercise. If that is not enough, further treatment is matched to the main problem. Psychological therapies are suggested for low mood or unhelpful ways of coping, medication for severe pain or disturbed sleep, and a combined rehabilitation program for severe disability (Macfarlane et al., 2017).
Medications give meaningful relief to a minority of people who take them.
- Pregabalin: in a Cochrane review, about 22 to 24 percent of people taking 300 to 600 milligrams a day had their pain cut by at least half, compared with about 14 percent on placebo (Derry et al., 2016).
- Duloxetine and milnacipran: 31 percent of people had their pain cut by at least half, compared with 21 percent on placebo. The reviewers judged that difference not clinically relevant, although more people on the drugs rated themselves much improved overall, 52 percent versus 29 percent (Welsch et al., 2018).
- The European recommendations also list low-dose amitriptyline, cognitive behavioral therapy, and multicomponent rehabilitation as options for people who do not improve with exercise and education alone. They advise against strong opioids and corticosteroids (Macfarlane et al., 2017).
Practical points
- Start activity low and build slowly. Walking, cycling, or water exercise two or three times a week is a common starting point. A temporary rise in soreness in the first weeks is expected.
- Treat sleep as part of the condition. Poor sleep makes pain worse, and problems such as sleep apnea or restless legs can be treated in their own right.
- Give a medication a fair trial at an adequate dose, and stop it if it is not helping. Most people in trials did not get substantial relief from any single drug.
- Keep track of other diagnoses. Fibromyalgia often occurs alongside other conditions, and a new or different symptom deserves its own evaluation.
When to see a doctor
Widespread pain lasting more than three months should be assessed, partly to check for conditions that can look similar and have specific treatments, such as an underactive thyroid or inflammatory arthritis. See a doctor promptly for joint swelling, fever, unexplained weight loss, muscle weakness, or numbness. These are not typical of fibromyalgia.
Sources
- The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey (Walitt et al., PLoS One, 2015) — analysis of the 2012 U.S. National Health Interview Survey
- A patient survey of the impact of fibromyalgia and the journey to diagnosis (Choy et al., BMC Health Services Research, 2010) — questionnaire survey of 800 patients and 1,622 physicians in eight countries
- 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (Wolfe et al., Seminars in Arthritis and Rheumatism, 2016) — revision of the American College of Rheumatology 2010/2011 diagnostic criteria
- Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia (Gracely et al., Arthritis & Rheumatism, 2002) — functional MRI study comparing patients with healthy volunteers
- Fibromyalgia: a clinical review (Clauw, JAMA, 2014) — clinical review
- A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis (Grayston et al., Seminars in Arthritis and Rheumatism, 2019) — systematic review and meta-analysis of 8 studies, n=222
- Passive transfer of fibromyalgia symptoms from patients to mice (Goebel et al., Journal of Clinical Investigation, 2021) — laboratory study transferring patient antibodies to mice
- Family study of fibromyalgia (Arnold et al., Arthritis & Rheumatism, 2004) — family study of 533 relatives of people with fibromyalgia and 272 relatives of people with rheumatoid arthritis
- EULAR revised recommendations for the management of fibromyalgia (Macfarlane et al., Annals of the Rheumatic Diseases, 2017) — European guideline based on 107 systematic reviews
- Aerobic exercise training for adults with fibromyalgia (Bidonde et al., Cochrane Database of Systematic Reviews, 2017) — Cochrane review of 13 randomized trials, n=839
- Pregabalin for pain in fibromyalgia in adults (Derry et al., Cochrane Database of Systematic Reviews, 2016) — Cochrane review of 8 randomized trials
- Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia (Welsch et al., Cochrane Database of Systematic Reviews, 2018) — Cochrane review of 18 randomized trials, n=7,903
This article is for general information and is not medical advice. Talk to your doctor before changing a medication, treatment or exercise program.



